Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM.
Devizzi L
J Clin Oncol. 2013 Jul 15;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Farina L
Leuk Lymphoma. 2013 Jun 14;55(2):331-6. doi: 10.3109/10428194.2013.802783
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Carlo-Stella C
PLoS One. 2013 Apr 19;8(4):e61603. doi: 10.1371/journal.pone.0061603
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Giacomini A
Angiogenesis. 2013 Apr 20;16(3):707-22. doi: 10.1007/s10456-013-9348-7
(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies.
Righi M
PLoS One. 2013 Mar 26;8(3):e59691. doi: 10.1371/journal.pone.0059691
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL
Leukemia. 2013 Jan 30;27(8):1677-87. doi: 10.1038/leu.2013.28
Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.
Magni M
Am J Blood Res. 2012 Apr 15;2(2):105-12.
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.
Lobetti-Bodoni C
Mech Ageing Dev. 2012 Jun 9;133(7):479-88. doi: 10.1016/j.mad.2012.05.007
The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
De Filippi P
Pediatr Blood Cancer. 2011 Dec 19;59(3):580-2. doi: 10.1002/pbc.23401
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Guidetti A
Br J Haematol. 2012 May 10;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x